In the present study, we are aimed to unveil CXCL12’s potential in the differential diagnosis of conditions mimicking amyotrophic lateral sclerosis symptoms and compare its capacity with the current gold standard, the CSF NF-L levels. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.